Image Place holder

Jonathan Zager, MD

Chief Academic Officer

Specialty: Surgery
Program: Cutaneous Oncology


Cancer Focus: Basal Cell Carcinoma, Melanoma, Sarcoma, Skin Cancer (Nonmelanoma)

Dr. Jonathan Zager is the Chief Academic Officer and a surgical oncologist and Senior Member in the Departments of Cutaneous Oncology and Sarcoma at Moffitt Cancer Center. Dr. Zager is the Director of Regional Therapies at Moffitt’s Donald A. Adam Comprehensive Melanoma Research Center. Dr. Zager is a Professor of Surgery at the University of South Florida, Morsani School of Medicine. Dr. Zager’s research and clinical interests include the regional therapy treatment of cutaneous melanoma and non-melanoma skin cancers, soft tissue sarcomas. Dr. Zager is internationally known for the management and study of locoregionally recurrent melanoma, non-melanoma skin cancer and soft tissue sarcoma. In particular conducting clinical trials for these clinical scenarios using regional therapies such as, intralesional injections using oncolytic viruses and isolated limb infusions for in transit or recurrent extremity melanoma and unresectable extremity sarcomas as well as performing percutaneous hepatic perfusions for unresectable melanoma to the liver. Dr. Zager graduated magna cum laude from Sackler School of Medicine’s New York State/American Program. He served a junior residency at North Shore University Hospital-New York University School of Medicine and was a research fellow at Memorial-Sloan Kettering Cancer Center before completing residency in surgery at Montefiore Medical Center-Albert Einstein College of Medicine, Where he was chief resident his last year. Dr. Zager completed fellowship training in surgical oncology at the University of Texas-M.D. Anderson Cancer Center. Dr. Zager has received numerous awards, including Best Doctors in America, America’s Top Oncologists, Top Doctors in Tampa Bay, Castle Connolly Top Doctors, Patients Choice Physician Awards and Clinical Educator and Mentor of the Year four times at Moffitt Cancer Center. He is a member of numerous editorial and advisory boards and professional organizations, including the Sentinel Node Oncology Foundation executive committee as well as the on the executive council of the Society of Surgical Oncology. Dr. Zager is the Director of Student Research in the Department of Cutaneous Oncology including the 8 week Summer Student Research Internship and the Program Director of the Surgical Oncology Research Fellowship Program.  Dr. Zager serves as Moffitt Cancer Center's Designated Institutional Official for their ACGME accreditation.

Education & Training


  • Memorial-Sloan Kettering Cancer Center - Hepatobiliary Oncology Laboratory
  • University of Texas, M.D. Anderson Cancer Center - Surgical Oncology
  • University of Texas, M.D. Anderson Cancer Center - Administrative Fellow


  • Montefiore Medical Center - Albert Einstein College of Medicine - Department of Surgery

Medical School:

  • Sackler School of Medicine - New York State American Program - MD
Start Year: 2009 End Year: Patient Satisfaction Award, Sponsor: Moffitt Cancer Center
Start Year: 2009 End Year: Faculty Clinical Mentor of the Year, Sponsor: Moffitt Cancer Center
Start Year: 2011 End Year: Mentor of the Year, Sponsor: Moffitt Cancer Center
Start Year: 2013 End Year: Faculty Clinical Mentor of the Year, Sponsor: Moffitt Cancer Center
Participating Trials

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10 (); Pembrolizumab (Keytruda)

An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients
Condition: Cutaneous
Intervention: Daromun (); Not Applicable ()

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Straker RJ, Song Y, Sun J, Shannon AB, Cohen LS, Muradova E, Daou H, Krause K, Li S, Frederick DT, Rhodin KE, Brizel DM, Boland GM, Beasley GM, Wuthrick EJ, Sondak VK, Zager JS, Lin A, Lukens JN, Karakousis GC. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul.28(7):3512-3521. Pubmedid: 33230747.
  • Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol. 2021 Feb.28(2):1007-1016. Pubmedid: 32524460.
  • Carr MJ, Kroon HM, Zager JS. ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. Ann Surg Oncol. 2020 Sep.27(13):5119-5120. Pubmedid: 32918180.
  • Carr MJ, Sun J, Kroon HM, Miura JT, Beasley GM, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Kirichenko DA, Potdar A, Daou H, Mullen D, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Ann Surg Oncol. 2020 Sep.27(13):5107-5118. Pubmedid: 32918177. Pmcid: PMC7674259.
  • Teras J, Kroon HM, Zager JS. ASO Author Reflection: Isolated Limb Infusion for Locally Advanced Melanoma in the Extremely Old Patient is Safe and Effective. Ann Surg Oncol. 2020 Mar.27(5):1430-1431. Pubmedid: 32144618.
  • Teras J, Kroon HM, Miura JT, Kenyon-Smith T, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Potdar A, Daou H, Sun J, Carr M, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Barbour A, Tyler DS, Coventry BJ, Zager JS, Thompson JF. International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Ann Surg Oncol. 2020 Mar.27(5):1420-1429. Pubmedid: 32152775.
  • Carr MJ, Sun J, Zager JS. Isolated limb infusion: Institutional protocol and implementation. J Surg Oncol. 2020 Mar.122(1):99-105. Pubmedid: 32162353.
  • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Jun.27(6):1978-1985. Pubmedid: 32103415.
  • Lee AY, Friedman EB, Sun J, Potdar A, Daou H, Farrow NE, Farley CR, Vetto JT, Han D, Tariq M, Shapiro R, Beasley G, Contreras CM, Osman I, Lowe M, Zager JS, Berman RS. The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. Ann Surg Oncol. 2020 Jun.27(13):5259-5266. Pubmedid: 32529271.
  • Sun J, Gastman BR, McCahon L, Buchbinder EI, Puzanov I, Nanni M, Lewis JM, Carvajal RD, Singh-Kandah S, Desai AM, Raskin L, Nielson CM, Ismail R, Zager JS. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Manag. 2020 Jun.7(2):MMT41. Pubmedid: 32821373. Pmcid: PMC7426742.
  • Han D, Han G, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?. Surgery. 2020 Jul.168(3):518-526. Pubmedid: 32669204.
  • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Jul.27(Suppl 3):983. Pubmedid: 32699930.
  • Prieto-Granada C, Castner N, Chen A, Li J, Yue B, Wong JY, Iyengar S, Sondak VK, Zager JS, Messina JL. Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathol Oncol Res. 2020 Jan.26(1):239-244. Pubmedid: 29948620. Pmcid: PMC6294697.
  • Miura JT, Zager JS. ASO Author Reflections: Robotic Pelvic Lymph Node Dissection for Metastatic Melanoma-A Minimally Invasive Approach to a Difficult Problem. Ann Surg Oncol. 2020 Jan.27(1):203-204. Pubmedid: 31286312.
  • Broman K, Zager J. An evaluation of talimogene laherparepvec for the treatment of melanoma. Expert Opin Biol Ther. 2020 Jan.20(1):9-14. Pubmedid: 31690129.
  • Pointer DT, Zager JS. Management of Locoregionally Advanced Melanoma. Surg Clin N Am. 2020 Feb.100(1):109-125. Pubmedid: 31753106.
  • Miura JT, Zager JS. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncol. 2019 Sep.15(32):3665-3674. Pubmedid: 31538818.
  • Broman KK, Zager JS. Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma. Melanoma Manag. 2019 Sep.6(3):MMT26. Pubmedid: 31807277. Pmcid: PMC6891941.
  • Sun J, Kirichenko DA, Zager JS, Eroglu Z. The emergence of neoadjuvant therapy in advanced melanoma. Melanoma Manag. 2019 Oct.6(3):MMT27. Pubmedid: 31807278. Pmcid: PMC6891937.
  • Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag. 2019 Oct.6(4):MMT33. Pubmedid: 31871622. Pmcid: PMC6923782.
  • Carr MJ, Sun J, Eroglu Z, Zager JS. An evaluation of encorafenib for the treatment of melanoma. Expert Opin Pharmacother. 2019 Nov.21(2):155-161. Pubmedid: 31790307.
  • Gyorki DE, Zager JS. Locoregional melanoma: identifying optimal care in a rapidly changing landscape. Melanoma Manag. 2019 Nov.6(3):MMT22. Pubmedid: 31807273. Pmcid: PMC6891935.
  • Broman KK, Dossett LA, Sun J, Eroglu Z, Zager JS. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf. 2019 May.18(5):381-392. Pubmedid: 30977681.
  • Perez MC, Sun J, Farley C, Han D, Sun AH, Narayan D, Lowe M, Delman KA, Messina JL, Gonzalez RJ, Sondak VK, Khushalani NI, Zager JS. Management of intussusception in patients with melanoma. J Surg Oncol. 2019 Jun.119(7):897-902. Pubmedid: 30734297.
  • Klemen ND, Han G, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Charney K, Hoekstra H, Sondak VK, Messina JL, Zager JS, Han D. Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. J Surg Oncol. 2019 Jun.119(8):1053-1059. Pubmedid: 30883771.
  • Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, White RL, Faries MB, Schneebaum S, Mozzillo N, Charney KJ, Sondak VK, Messina JL, Zager JS, Han D. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. Ann Surg Oncol. 2019 Jul.26(7):2254-2262. Pubmedid: 31011906.
  • Perez MC, Zager JS, Amatruda T, Conry R, Ariyan C, Desai A, Kirkwood JM, Treichel S, Cohan D, Raskin L. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). Melanoma Manag. 2019 Jul.6(2):MMT19. Pubmedid: 31406563. Pmcid: PMC6688558.
  • Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan.125(1):18-44. Pubmedid: 30281145. Pmcid: PMC6860362.
  • Karakousis GC, Gimotty PA, Leong SP, Pockaj BA, White RL, O'Donoghue C, Sinnamon AJ, Bartlett EK, Dueck AC, Gould Rothberg BE, Messina JL, Vetto JT, Sondak VK, Schneebaum S, Kashani-Sabet M, Han D, Faries MB, Zager JS. Microsatellitosis in Patients with Melanoma. Ann Surg Oncol. 2019 Jan.26(1):33-41. Pubmedid: 30421045.
  • Hanna AN, Sinnamon AJ, Roses RE, Kelz RR, Elder DE, Xu X, Pockaj BA, Zager JS, Fraker DL, Karakousis GC. Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): A National Cancer Database study. J Am Acad Dermatol. 2019 Feb.80(2):433-440. Pubmedid: 30165160.
  • Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
  • Miura JT, Kroon HM, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Potdar A, Daou H, Sun J, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Mark Smithers B, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. Ann Surg Oncol. 2019 Aug.26(8):2486-2494. Pubmedid: 30911949. Pmcid: PMC7771312.
  • Miura JT, Kroon HM, Zager JS. ASO Author Reflections: International Experience of Isolated Limb Infusion for Melanoma Shows Durable Response. Ann Surg Oncol. 2019 Aug.26(8):2495-2496. Pubmedid: 31087177.
  • Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, Liu K, Hsu CP, Pickett CA, Mehnert JM. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019 Aug.47:89-97. Pubmedid: 31409575. Pmcid: PMC6796514.
  • Beasley GM, Zager JS, Thompson JF. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Ann Surg Oncol. 2019 Aug.27(1):35-42. Pubmedid: 31471842.
  • Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, Lowe M, Sarnaik AA, Zager JS, Ollila DW. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. J Am Coll Surg. 2019 Apr.228(4):644-649. Pubmedid: 30690076.
  • Miura JT, Dossett LA, Thapa R, Kim Y, Potdar A, Daou H, Sun J, Sarnaik AA, Zager JS. Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. Ann Surg Oncol. 2019 Apr.27(1):196-202. Pubmedid: 30949862. Pmcid: PMC7771311.
  • Weitman ES, Perez MC, Lee D, Kim Y, Fulp W, Sondak VK, Sarnaik AA, Gonzalez RJ, Cruse CW, Messina JL, Zager JS. Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. Melanoma Manag. 2019 Apr.6(2):MMT17. Pubmedid: 31406562. Pmcid: PMC6688556.
  • Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
  • Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, Pearce N, Takhar A, Gupta S, Hardman D, Sileno S, Stedman B, Zager JS, Ottensmeier C. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018 May.117(6):1170-1178. Pubmedid: 29284076. Pmcid: PMC6033148.
  • Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT. Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer. 2018 May.124(10):2254-2255. Pubmedid: 29543319.
  • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
  • Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Manag. 2018 Jun.5(1):MMT02. Pubmedid: 30190928. Pmcid: PMC6122528.
  • Perez MC, Orcutt ST, Zager JS. Current standards of surgical management in primary melanoma. G Ital Dermatol Venereol. 2018 Feb.153(1):56-67. Pubmedid: 28895666.
  • Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb.25(2):356-377. Pubmedid: 29236202.
  • Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 Feb.36(4):399-413. Pubmedid: 29232171.
  • Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018 Feb.18(1):130. Pubmedid: 29402264. Pmcid: PMC5800282.
  • Perez MC, Zager JS. ASO Author Reflections: Resection Margins in Merkel Cell Carcinoma: Is a 1 cm Margin Wide Enough?. Ann Surg Oncol. 2018 Dec.25(Suppl 3):901. Pubmedid: 30151562.
  • Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, Sarnaik AA, Zager JS. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Ann Surg Oncol. 2018 Dec.25(13):3960-3965. Pubmedid: 30298318. Pmcid: PMC7771271.
  • Rothermel LD, Zager JS. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?. Expert Opin Biol Ther. 2018 Dec.18(12):1199-1207. Pubmedid: 30392405.
  • Sun J, Zager JS, Eroglu Z. Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Targets Ther. 2018 Dec.11:9081-9089. Pubmedid: 30588020. Pmcid: PMC6299465.
  • Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS. Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clin Exp Metastas. 2018 Aug.35(5-6):487-493. Pubmedid: 29722000.
  • Weitman ES, Zager JS. Regional therapies for locoregionally advanced and unresectable melanoma. Clin Exp Metastas. 2018 Aug.35(5-6):495-502. Pubmedid: 29736626.
  • Leong SP, Zager JS. Editorial. Clin Exp Metastas. 2018 Aug.35(5-6):359-360. Pubmedid: 29796855.
  • Leong SP, Zager JS. Future perspectives: cancer metastases. Clin Exp Metastas. 2018 Aug.35(5-6):559-561. Pubmedid: 30039283.
  • Weitman ES, Perez M, Thompson JF, Andtbacka RHI, Dalton J, Martin ML, Miller T, Gwaltney C, Sarson D, Wachter E, Zager JS. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Res. 2018 Apr.28(2):134-142. Pubmedid: 29261570. Pmcid: PMC5844587.
  • Miura JT, Zager JS. Intralesional therapy as a treatment for locoregionally metastatic melanoma. Expert Rev Anticancer Ther. 2018 Apr.18(4):399-408. Pubmedid: 29466885.
  • Chang JM, Kosiorek HE, Dueck AC, Leong SPL, Vetto JT, White RL, Avisar E, Sondak VK, Messina JL, Zager JS, Garberoglio C, Kashani-Sabet M, Pockaj BA. Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg. 2018 Apr.215(4):699-706. Pubmedid: 29502857. Pmcid: PMC5978691.
  • Burke EE, Zager JS. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Metab Toxicol. 2018 Apr.14(4):469-473. Pubmedid: 29557682.
  • Saco M, Zager J, Messina J. Metastatic melanoma and prostatic adenocarcinoma in the same sentinel lymph node. Cutis. 2018 02.101(2):E1-E3. Pubmedid: 29554169.
  • Rossfeld K, Hade EM, Gangi A, Perez M, Kinsey EN, Grabska J, Ederle A, Zager J, Salama AK, Olencki TE, Beasley GM. Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. Int J Surg Oncol (N Y). 2017 Oct.2(9):e43. Pubmedid: 29177235. Pmcid: PMC5673131.
  • Schuitevoerder D, Leong SPL, Zager JS, White RL, Avisar E, Kosiorek H, Dueck A, Fortino J, Kashani-Sabet M, Hart K, Vetto JT. Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. Am J Surg. 2017 May.213(5):921-925. Pubmedid: 28411863.
  • Glazer ES, Porubsky CF, Francis JD, Ibanez J, Castner N, Messina JL, Sarnaik AA, Harrington MA, Cruse CW, Sondak VK, Zager JS. Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Ann Plast Surg. 2017 Jun.78(6):663-667. Pubmedid: 27984218. Pmcid: PMC5425303.
  • Naghavi AO, Gonzalez RJ, Scott JG, Mullinax JE, Abuodeh YA, Kim Y, Binitie O, Ahmed KA, Bui MM, Saini AS, Zager JS, Biagioli MC, Letson D, Harrison LB, Fernandez DC. Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. Brachytherapy. 2017 Jul.15(4):495-503. Pubmedid: 27180128. Pmcid: PMC7771533.
  • Glazer ES, Zager JS. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases. Cancer Control. 2017 Jan.24(1):96-101. Pubmedid: 28178721.
  • Doepker MP, Yamamoto M, Applebaum MA, Patel NU, Jaime Montilla-Soler M, Sarnaik AA, Wayne Cruse C, Sondak VK, Zager JS. Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. Ann Surg Oncol. 2017 Feb.24(2):355-361. Pubmedid: 27660259. Pmcid: PMC5955617.
  • Gangi A, Zager JS. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2017 Feb.16(2):265-269. Pubmedid: 27989216.
  • Neuwirth MG, Song Y, Sinnamon AJ, Fraker DL, Zager JS, Karakousis GC. Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. Ann Surg Oncol. 2017 Dec.24(13):3803-3810. Pubmedid: 29022281.
  • O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH, Kim Y, Gonzalez RJ, Zager JS. Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Ann Surg Oncol. 2017 Dec.24(13):3842-3849. Pubmedid: 29019175. Pmcid: PMC7771340.
  • Chai C, Szabunio M, Cook C, Zager J, Messina J, Chau A, Sondak V. Pre-SN Ultrasound-FNAC for Lymph Node Metastases in Melanoma Patients: A Reply. Ann Surg Oncol. 2017 Dec.24(Suppl 3):663-664. Pubmedid: 29134381.
  • Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DS, Thompson J, Mozzillo N, Nieweg OE, Noyes D, Hoekstra HJ, Zager JS, Roses DF, Testori A, Coventry BJ, Smithers MB, Andtbacka R, Agnese D, Schultz E, Hsueh EC, Kelley M, Schneebaum S, Jacobs L, Bowles T, Kashani-Sabet M, Johnson D, Faries MB. The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Ann Surg Oncol. 2017 Aug.24(8):2089-2094. Pubmedid: 28224364. Pmcid: PMC5553293.
  • Mullinax JE, Gonzalez RJ, Zager JS. Treatment of Soft Tissue Sarcoma: In reply to He and colleagues. J Am Coll Surg. 2017 Aug.225(2):349. Pubmedid: 28750715.
  • Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, Bhati R, Hardmann D, Sileno S, O'Donoghue C, Perez M, Naqvi SM, Chen YA, Gonzalez RJ, Zager JS. Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. J Am Coll Surg. 2017 Apr.224(4):635-642. Pubmedid: 28214556. Pmcid: PMC7771304.
  • Sondak VK, Messina JL, Zager JS. Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy-This Time It's Personal. JAMA Dermatol. 2017 09.153(9):857-858. Pubmedid: 28724141.
  • DePeralta DK, Zager JS. Metastasectomy for Abdominal Visceral Oligometastatic Melanoma. JAMA Surg. 2017 07.152(7):678. Pubmedid: 28384678.
  • Kim DW, Zager JS, Eroglu Z. Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. Chin Clin Oncol. 2017 02.6(1):2. Pubmedid: 28285535.
  • Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016 Oct.23(11):3572-3578. Pubmedid: 27251134.
  • Parekh A, Strom T, Naghavi AO, Caudell JJ, Zager JS, Messina JL, Torres-Roca JF, Sondak VK, Trotti A, Harrison LB. Does Regional Radiation Therapy Impact Outcome for High-Risk, Node-Positive Cutaneous Melanoma?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):S157. Pubmedid: 27675666.
  • Sarnaik AA, Zager JS, Sondak VK. Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma. Oncology (Williston Park). 2016 Oct.30(10):891-2-895. Pubmedid: 27753054.
  • Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS. Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg. 2016 Nov.82(11):1109-1116. Pubmedid: 28206940.
  • Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS. Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg. 2016 Nov.82(11):1109-1116. Pubmedid: 28877811.
  • Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Ann Surg Oncol. 2016 Jul.23(7):2330-2335. Pubmedid: 26926481.
  • Doepker MP, Thompson ZJ, Fisher KJ, Yamamoto M, Nethers KW, Harb JN, Applebaum MA, Gonzalez RJ, Sarnaik AA, Messina JL, Sondak VK, Zager JS. Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?. Ann Surg Oncol. 2016 Jul.23(7):2336-2342. Pubmedid: 26957503. Pmcid: PMC4904729.
  • Doepker MP, Thompson ZJ, Harb JN, Messina JL, Puleo CA, Egan KM, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. J Surg Oncol. 2016 Jan.113(1):98-102. Pubmedid: 26661407. Pmcid: PMC4904728.
  • Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016 Jan.23(1):12-20. Pubmedid: 27009452. Pmcid: PMC4904721.
  • Otto K, Zager JS. Art, Science, and Personalized Cancer Care Through Regional Therapeutics. Cancer Control. 2016 Jan.23(1):3-4. Pubmedid: 27009450.
  • Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016 Feb.26(1):83-87. Pubmedid: 26731560.
  • Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016 Dec.16(12):1491-1499. Pubmedid: 27602429.
  • Hassani J, Porubsky C, Berman C, Zager J, Messina J, Henderson-Jackson E. Intraperitoneal Rosai-Dorfman disease associated with clear cell sarcoma: first case report. Pathology. 2016 Dec.48(7):742-744. Pubmedid: 27814905.
  • O'Donoghue C, Doepker MP, Zager JS. Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Manag. 2016 Dec.3(4):267-272. Pubmedid: 30190898. Pmcid: PMC6094674.
  • Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J, McCluskey K, Whitman E, Agarwala S, Siskin G, Nutting C, Toomey MA, Webb C, Beresnev T, Pingpank JF. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann Surg Oncol. 2016 Apr.23(4):1309-1319. Pubmedid: 26597368. Pmcid: PMC8185532.
  • Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS. Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg. 2016 Apr.222(4):702-709. Pubmedid: 26875071. Pmcid: PMC4871144.
  • Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015 Sep.121(18):3252-3260. Pubmedid: 26038193. Pmcid: PMC4904725.
  • Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep.33(25):2780-2788. Pubmedid: 26014293.
  • DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R, Robinson L, Zager JS, Gonzalez RJ, Sondak VK, Letson GD, Conley A. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. PLoS One. 2015 Oct.10(10):e0140362. Pubmedid: 26469269. Pmcid: PMC4607370.
  • Rashid OM, Zager JS. Genetic Testing in the Multidisciplinary Management of Melanoma. Surg Oncol Clin N Am. 2015 Oct.24(4):779-793. Pubmedid: 26363541.
  • Yamamoto M, Fisher KJ, Wong JY, Koscso JM, Konstantinovic MA, Govsyeyev N, Messina JL, Sarnaik AA, Cruse CW, Gonzalez RJ, Sondak VK, Zager JS. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 2015 May.121(10):1628-1636. Pubmedid: 25677366. Pmcid: PMC4515965.
  • Han D, Han G, Zhao X, Rao NG, Messina JL, Marzban SS, Sarnaik AA, Cruse CW, Sondak VK, Zager JS. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One. 2015 Mar.10(3):e0119716. Pubmedid: 25811671. Pmcid: PMC4374691.
  • Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul.112(1):103-106. Pubmedid: 26179670.
  • Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, Mosca PJ, Royal R, Ross M, Zager JS, Tyler DS. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Ann Surg Oncol. 2015 Jan.22(1):287-294. Pubmedid: 25145500. Pmcid: PMC4464816.
  • Muilenburg DJ, Beasley GM, Thompson ZJ, Lee JH, Tyler DS, Zager JS. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2015 Feb.22(2):482-488. Pubmedid: 25192683. Pmcid: PMC4505812.
  • Glazer ES, Prieto-Granada C, Zager JS. Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. Curr Prob Cancer. 2015 Aug.39(4):248-257. Pubmedid: 26276213.
  • Doepker MP, Zager JS. Sentinel lymph node mapping in melanoma in the twenty-first century. Surg Oncol Clin N Am. 2015 Apr.24(2):249-260. Pubmedid: 25769710.
  • Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf. 2015 Apr.14(4):559-570. Pubmedid: 25648338.
  • Rashid OM, Sloot S, Zager JS. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2014 Oct.10(10):1355-1364. Pubmedid: 25176398.
  • Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin N Am. 2014 Oct.94(5):1003-15, viii. Pubmedid: 25245964.
  • Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, Marzban SS, Messina JL, Trotti AM, Sondak VK, Rao NG. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014 May.120(9):1369-1378. Pubmedid: 24142775. Pmcid: PMC4515972.
  • Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea J, Lim SJ, Cochran AJ, Meyskens FL. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014 May.7(5):496-504. Pubmedid: 24614012. Pmcid: PMC4208700.
  • Sondak VK, Zager JS. Melanoma: MSLT-1--putting sentinel lymph node biopsy into context. Nat Rev Clin Oncol. 2014 May.11(5):246-248. Pubmedid: 24732944.
  • Yamamoto M, Zager JS. Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol. 2014 Mar.109(4):383-388. Pubmedid: 24166748.
  • Agarwala SS, Eggermont AM, O'Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014 Mar.120(6):781-789. Pubmedid: 24301420.
  • Zager JS, Messina JL, Glass LF, Sondak VK. Unanswered questions in the management of stage I-III Merkel cell carcinoma. J Natl Compr Canc Ne. 2014 Mar.12(3):425-431. Pubmedid: 24616546.
  • Toloza E, Rodriguez K, Sobky C, Brown L, Garrett J, Chai C, Moodie C, Bhati R, Mosiello G, Zager J. Interclavicular stabilization with the synthes sternal fixation system after radical manubriectomy: report of 3 cases. Chest. 2014 Mar.145(3 Suppl):35A. Pubmedid: 24638364.
  • Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA. Occult primary, version 3.2014. J Natl Compr Canc Ne. 2014 Jul.12(7):969-974. Pubmedid: 24994917.
  • Thareja S, Zager JS, Sadhwani D, Thareja S, Chen R, Marzban S, Jukic DM, Glass LF, Messina J. Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain. Am J Dermatopathxxx. 2014 Jan.36(1):64-67. Pubmedid: 24451214. Pmcid: PMC5764097.
  • Wong J, Ann Chen Y, Fisher KJ, Beasley GM, Tyler DS, Zager JS. Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. Ann Surg Oncol. 2014 Feb.21(2):650-655. Pubmedid: 24162840. Pmcid: PMC4504422.
  • Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014 Dec.15(18):2629-2639. Pubmedid: 25381015.
  • Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR. Recent developments in the medical and surgical treatment of melanoma. CA-Cancer J Clin. 2014 Aug.64(3):171-185. Pubmedid: 24676837.
  • Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014 Apr.109(5):434-439. Pubmedid: 24249545. Pmcid: PMC4503311.
  • de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford). 2013 Sep.15(9):655-660. Pubmedid: 23458233. Pmcid: PMC3948531.
  • Perez MC, Padhya TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, Letson GD, Cruse CW, Lavey RS, Cheong D, Forster MR, Fulp WJ, Sondak VK, Zager JS. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol. 2013 Oct.20(11):3391-3397. Pubmedid: 23835652. Pmcid: PMC4509495.
  • Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013 Oct.20(4):248-254. Pubmedid: 24077401. Pmcid: PMC4516026.
  • Deneve JL, Messina JL, Bui MM, Marzban SS, Letson GD, Cheong D, Gonzalez RJ, Sondak VK, Zager JS. Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control. 2013 Oct.20(4):307-312. Pubmedid: 24077407. Pmcid: PMC4504421.
  • Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR. Recent advances in the treatment of melanoma. Cancer Control. 2013 Oct.20(4):244-245. Pubmedid: 24077400.
  • Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg. 2013 May.79(5):476-482. Pubmedid: 23635582. Pmcid: PMC4505800.
  • Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia. 2013 Jun.29(1):1-7. Pubmedid: 23205633. Pmcid: PMC4509503.
  • Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Ne. 2013 Jun.11(6):679-686. Pubmedid: 23744867. Pmcid: PMC4530628.
  • Han D, Zager JS, Yu D, Zhao X, Walls B, Marzban SS, Rao NG, Sondak VK, Messina JL. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?. Ann Surg Oncol. 2013 Jul.20(7):2345-2351. Pubmedid: 23389470. Pmcid: PMC4503324.
  • Gibney GT, Zager JS. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Jul.9(7):893-899. Pubmedid: 23621583.
  • Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, Faries MB, Averbook BJ, Martinez SR, Puleo CA, Messina JL, Christman L, Wallace AM. Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013 Feb.20(2):680-688. Pubmedid: 23054107. Pmcid: PMC3560941.
  • Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013 Dec.31(35):4387-4393. Pubmedid: 24190111.
  • Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park JY, Rollison DE. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol. 2013 Aug.37(4):434-439. Pubmedid: 23523330. Pmcid: PMC3679277.
  • Farma JM, Zager JS, Barnica-Elvir V, Puleo CA, Marzban SS, Rollison DE, Messina JL, Sondak VK. A collision of diseases: chronic lymphocytic leukemia discovered during lymph node biopsy for melanoma. Ann Surg Oncol. 2013 Apr.20(4):1360-1364. Pubmedid: 23179994. Pmcid: PMC4606461.
  • Wong J, Chen YA, Fisher KJ, Zager JS. Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol. 2013 Apr.20(4):1121-1127. Pubmedid: 23456376. Pmcid: PMC4504423.
  • Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Wayne Cruse C, Sarnaik AA, Puleo C, Sondak VK, Zager JS. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol. 2012 Oct.19(11):3335-3342. Pubmedid: 22766986. Pmcid: PMC4504019.
  • Sondak VK, Zager JS, Messina JL. Primary tumor thickness as a prognostic factor in Merkel cell carcinoma: the next big thing?. Ann Surg Oncol. 2012 Oct.19(11):3307-3309. Pubmedid: 22825775.
  • Leong SP, Mihm MC, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastas. 2012 Oct.29(7):775-796. Pubmedid: 22892755. Pmcid: PMC4311146.
  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct.35(8):615-620. Pubmedid: 22996367. Pmcid: PMC4467830.
  • Leong SP, Mihm MC, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM. Erratum to: Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct.29(7):797-799. Pubmedid: 23053741.
  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov.19(12):3888-3895. Pubmedid: 22864798. Pmcid: PMC4519977.
  • Chai CY, Deneve JL, Beasley GM, Marzban SS, Chen YA, Rawal B, Grobmyer SR, Hochwald SN, Tyler DS, Zager JS. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012 May.19(5):1637-1643. Pubmedid: 22143576. Pmcid: PMC4515968.
  • Mills OL, Marzban S, Zager JS, Sondak VK, Messina JL. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol. 2012 Mar.39(3):331-336. Pubmedid: 22335592.
  • Deneve JL, Messina JL, Marzban SS, Gonzalez RJ, Walls BM, Fisher KJ, Ann Chen Y , Wayne Cruse C, Sondak VK, Zager JS. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol. 2012 Jul.19(7):2360-2366. Pubmedid: 22271206. Pmcid: PMC4504007.
  • Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012 Feb.82(2):924-932. Pubmedid: 21398051. Pmcid: PMC4241354.
  • Parsons CM, Pimiento JM, Cheong D, Marzban SS, Gonzalez RJ, Johnson D, Letson GD, Zager JS. The role of radical amputations for extremity tumors: a single institution experience and review of the literature. J Surg Oncol. 2012 Feb.105(2):149-155. Pubmedid: 21837679. Pmcid: PMC4504014.
  • Beasley GM, Sharma K, Wong J, Miller M, Turley RS, Lidsky M, Masoud M, Dewhirst MW, Mosca PJ, Zager JS, Tyler DS. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer. 2012 Dec.118(24):6136-6143. Pubmedid: 22674423. Pmcid: PMC5161098.
  • Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, Werner P, Chaudhry TA, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol. 2012 Dec.35(6):1480-1487. Pubmedid: 22699779.
  • Beasley GM, Parsons C, Broadwater G, Selim MA, Marzban S, Abernethy AP, Salama AK, Eikman EA, Wong T, Zager JS, Tyler DS. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg. 2012 Aug.256(2):350-356. Pubmedid: 22691370. Pmcid: PMC4618558.
  • Chai CY, Zager JS, Szabunio MM, Marzban SS, Chau A, Rossi RM, Sondak VK. Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Ann Surg Oncol. 2012 Apr.19(4):1100-1106. Pubmedid: 22193886. Pmcid: PMC4504035.
  • Deneve JL, Zager JS. Isolated regional therapy for advanced extremity soft tissue sarcomas. Surg Oncol Clin N Am. 2012 Apr.21(2):287-299. Pubmedid: 22365520.
  • Marcum CB, Zager JS, Bélongie IP, Messina JL, Fenske NA. Profound proliferating angiolymphoid hyperplasia with eosinophilia of pregnancy mimicking angiosarcoma. Cutis. 2011 Sep.88(3):122-128. Pubmedid: 22017064.
  • Zager JS, Puleo CA, Sondak VK. What is the significance of the in transit or interval sentinel node in melanoma?. Ann Surg Oncol. 2011 Nov.18(12):3232-3234. Pubmedid: 21837524.
  • Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2011 Nov.7(11):1383-1394. Pubmedid: 21978383. Pmcid: PMC4630979.
  • Zager JS, Rollison DE, Messina J. Prognostication in Merkel cell carcinoma. Expert Rev Anticanc. 2011 May.11(5):665-667. Pubmedid: 21554038.
  • Beasley GM, Riboh JC, Augustine CK, Zager JS, Hochwald SN, Grobmyer SR, Peterson B, Royal R, Ross MI, Tyler DS. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011 Mar.29(9):1210-1215. Pubmedid: 21343562. Pmcid: PMC4668281.
  • Cheong D, Gonzalez RJ, Zager JS. Strategies for solutions in sarcoma management. Cancer Control. 2011 Jul.18(3):148-149. Pubmedid: 21666576.
  • Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. Cancer Control. 2011 Jul.18(3):177-187. Pubmedid: 21666580.
  • Turaga KK, Beasley GM, Kane JM, Delman KA, Grobmyer SR, Gonzalez RJ, Letson GD, Cheong D, Tyler DS, Zager JS. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg. 2011 Jul.146(7):870-875. Pubmedid: 21768436. Pmcid: PMC4515974.
  • Zager JS, Puleo CA, Sondak VK. Erratum to: What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?. Ann Surg Oncol. 2011 Dec.18 Suppl 3:317-318. Pubmedid: 22048634.
  • Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK. NCCN Clinical Practice Guidelines Occult primary. J Natl Compr Canc Ne. 2011 Dec.9(12):1358-1395. Pubmedid: 22157556.
  • Zager JS, Hochwald SN, Marzban SS, Francois R, Law KM, Davis AH, Messina JL, Vincek V, Mitchell C, Church A, Copeland EM, Sondak VK, Grobmyer SR. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg. 2011 Apr.212(4):454-460. Pubmedid: 21463767. Pmcid: PMC4505798.
  • Santillan AA, Zager JS. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Expert Opin Drug Metab Toxicol. 2010 Sep.6(9):1033-1037. Pubmedid: 20078252.
  • Chu CK, Zager JS, Marzban SS, Gimbel MI, Murray DR, Hestley AC, Messina JL, Sondak VK, Carlson GW, Delman KA. Routine biopsy of Cloquet's node is of limited value in sentinel node positive melanoma patients. J Surg Oncol. 2010 Sep.102(4):315-320. Pubmedid: 20740592.
  • Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma?. Ann Surg Oncol. 2010 Mar.17(3):670-673. Pubmedid: 19953329. Pmcid: PMC2820671.
  • Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm Is Not Justified. J Clin Oncol. 2010 Jan.28(1):e7-e7. Pubmedid: 19933899.
  • Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010 Jan.28(3):481-486. Pubmedid: 20008627.
  • Zager JS, Delman KA. Commentary on pharmacotherapy of regional melanoma therapy. Expert Opin Pharmaco. 2010 Jan.11(1):1-3. Pubmedid: 20001424.
  • Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, Johnson TM, Lowe L, Sabel MS, Wong SL, Letson GD, Messina JL, Cimmino VM, Sondak VK. Dermatofibrosarcoma protuberans: how wide should we resect?. Ann Surg Oncol. 2010 Aug.17(8):2112-2118. Pubmedid: 20354798.
  • Feeney K, Maguire HC, McClay EF, Sato T, Sondak VK, Toporcer M, Zager JS. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?. Semin Oncol. 2010 Aug.37(4):303-313. Pubmedid: 20816500.
  • Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009 Sep.16(9):2570-2578. Pubmedid: 19543771.
  • Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009 May.208(5):706-715. Pubmedid: 19476821.
  • Möller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, Kinal A, Clark GS, Zhu W, Puleo CA, Glass LF, Messina JL, Sondak VK, Cruse CW. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009 Jun.16(6):1526-1536. Pubmedid: 19050971.
  • Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009 Jul.16(3):234-239. Pubmedid: 19556963.
  • Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009 Jul.16(3):240-247. Pubmedid: 19556964.
  • Zager JS, Weber JS. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II. Cancer Control. 2009 Jul.16(3):196-197. Pubmedid: 19556959.
  • Zager J, Bui M, Farma J, Messina J, Sondak V. Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow?. Ann Surg Oncol. 2008 Sep.15(9):2614-2616. Pubmedid: 18452044.
  • Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Ne. 2008 Nov.6(10):1026-1060. Pubmedid: 19176200.
  • Moller M, Lewis J, Dessureault S, Zager J. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008 May.24(3):275-289. Pubmedid: 18393005.
  • Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects. Ann Surg Oncol. 2008 Jun.15(6):1733-1740. Pubmedid: 18379848.
  • Zager J, Daud A. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control. 2008 Jul.15(3):192-194. Pubmedid: 18596670.
  • Gimbel M, Delman K, Zager J. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control. 2008 Jul.15(3):225-232. Pubmedid: 18596674.
  • McLoughlin J, Zager J, Sondak V, Berk L. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008 Jul.15(3):239-247. Pubmedid: 18596676.
  • Melis M, Zager J, Sondak V. Multimodality management of desmoid tumors: how important is a negative surgical margin?. J Surg Oncol. 2008 Dec.98(8):594-602. Pubmedid: 19072851.
  • Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007 Sep.9(5):417-427. Pubmedid: 17706171.
  • Sondak V, Zager J, Messina J, Thomas J. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007 Jun.5(6):483-490. Pubmedid: 17679922.
  • Gannon C, Zager J, Chang G, Feig B, Wood C, Skibber J, Rodriguez-BigasMA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007 Jun.14(6):1870-1877. Pubmedid: 17406945.
  • McLoughlin J, Zager J, Sondak V. Cytoreductive surgery for melanoma. Surg Oncol Clin N Am. 2007 Jul.16(3):683-693. Pubmedid: 17606201.
  • Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery. 2007 Apr.141(4):520-529. Pubmedid: 17383529. Pmcid: PMC2559995.
  • Khakpour N, Zager J, Yen T, Stephens T, Kuerer H, Singletary E, Ross M, Hunt K, Babiera G. The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. Breast J. 2006 May.12(3):212-215. Pubmedid: 16684318.
  • Jarnagin W, Zager J, Hezel M, Stanziale S, Adusumilli P, Gonen M, EbrightMI, Culliford A, Gusani N, Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 2006 Mar.13(3):326-334. Pubmedid: 16138120.
  • Lin Y, Deavers M, Sasan F, Zager J, Ramondetta L. Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol. 2006 Dec.103(3):1159-1163. Pubmedid: 17055558.
  • Kaleya R, Heckman J, Most M, Zager J. Lymphatic mapping and sentinel node biopsy: a surgical perspective. Semin Nucl Med. 2005 Apr.35(2):129-134. Pubmedid: 15765375.
  • Delman K, Zager J, Bhargava A, Petrowsky H, Malhotra S, Ebright M, BennettJJ, Gusani N, Kooby D, Roberts G, Fong Y. Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. Hepatology. 2004 Jun.39(6):1525-1532. Pubmedid: 15185293.
  • Bocker J, Vasile J, Zager J, Goodman E. Intussusception: an uncommon cause of postoperative small bowel obstruction after gastric bypass. Obes Surg. 2004 Jan.14(1):116-119. Pubmedid: 14980045.
  • Zager J, Delman K, Ebright M, Malhotra S, Larson S, Fong Y. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver. Br J Surg. 2003 Oct.90(10):1225-1231. Pubmedid: 14515291.
  • Zager J, Ohki T, Simon J, Gruber B, Zoe H, Teperman S, Stone ME J, VeithFJ, Simon R. Endovascular repair of a traumatic pseudoaneurysm of the thoracic aorta in a patient with concomitant intracranial and intra-abdominal injuries. J Trauma. 2003 Oct.55(4):778-781. Pubmedid: 14566138.
  • Jarnagin W, Zager J, Klimstra D, Delman K, Malhotra S, Ebright M, LittleS, DeRubertis B, Stanziale S, Hezel M, Federoff H, Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects againstrecurrence-after resection. Cancer Gene Ther. 2003 Mar.10(3):215-223. Pubmedid: 12637943.
  • Delman KA, Zager JS, Bennett JJ, Malhotra S, Ebright MI, McAuliffe PF, Halterman MW, Federoff HJ, Fong Y. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg. 2002 Sep.236(3):337-342. Pubmedid: 12192320. Pmcid: PMC1422587.
  • Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 2002 Nov.9(11):935-945. Pubmedid: 12386832.
  • Ebright M, Zager J, Malhotra S, Delman K, Weigel T, Rusch V, Fong Y. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg. 2002 Jul.124(1):123-129. Pubmedid: 12091817.
  • Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, Gonen M, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery. 2002 Aug.132(2):353-359. Pubmedid: 12219034.
  • Paris F, Grassme H, Cremesti A, Zager J, Fong Y, Haimovitz-Friedman A, Fuks Z, Gulbins E, Kolesnick R. Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes. J Biol Chem. 2001 Mar.276(11):8297-8305. Pubmedid: 11096096.
  • Bennett J, Malhotra S, Wong R, Delman K, Zager J, St-Louis M, Johnson P, Fong Y. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg. 2001 Jun.233(6):819-826. Pubmedid: 11371740.
  • Zager J, Gusani N, Derubertis B, Shaw J, Kaufman J, DeNoto G. Laparoscopic appendectomy for Crohn's disease of the appendix presenting as acute appendicitis. J Laparoendosc Adv Surg Tech A. 2001 Aug.11(4):255-258. Pubmedid: 11569518.
  • Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T, Halterman M, Federoff H, Fong Y. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med. 2001 Aug.7(8):561-568. Pubmedid: 11591892. Pmcid: PMC1950059.
  • Zager J, Shaw J, Kaufman J, DeNoto G. Three cases of small bowel intussusception in relation to a rare lesion: inflammatory fibrous polyps. Dig Surg. 2001.18(2):142-146. Pubmedid: 11351161.
  • Cohen M, Greenwald M, Garbus J, Zager J. Granular cell tumor--a unique neoplasm of the internal anal sphincter: report of a case. Dis Colon Rectum. 2000 Oct.43(10):1444-1446. Pubmedid: 11052524.
  • Jarnagin W, Delman K, Kooby D, Mastorides S, Zager J, Brennan M, BlumgartLH, Federoff H, Fong Y. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg. 2000 May.231(5):762-771. Pubmedid: 10767798.
  • Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, Kooby DA, Hawkins WG, Horsburgh BC, Johnson P, Fong Y. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther. 2000 Dec.11(18):2465-2472. Pubmedid: 11119418.
  • Zager J, Garbus J, Shaw J, Cohen M, Garber S. Jejunal diverticulosis: a rare entity with multiple presentations, a series of cases. Dig Surg. 2000.17(6):643-645. Pubmedid: 11155015.
  • Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, Cruse CW, Zager JS. The surgical management of primary and metastatic Merkel cell carcinoma. Curr Prob Cancer. 34(1):77-96. Pubmedid: 20371076.
  • McCardle TW, Sondak VK, Zager J, Messina JL. Merkel cell carcinoma: pathologic findings and prognostic factors. Curr Prob Cancer. 34(1):47-64. Pubmedid: 20371074.
  • Zager JS, Brodsky S, Berman CG. Imaging of Merkel cell carcinoma. Curr Prob Cancer. 34(1):65-76. Pubmedid: 20371075.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments